Disease progression, or gradual worsening, experienced by people who have multiple sclerosis usually occurs over many years, and it is difficult to track with the standard clinical measurement scales used by doctors to assess disease activity.
An international meeting was convened to determine how to improve clinical measures so that MS progression can be better tracked, especially during clinical trials of experimental therapies aimed at stopping progression. Better ways of measuring changes in disability will help to speed the development of new therapies for MS, in particular for progressive forms of the disease.
The meeting was organized by the International Advisory Committee on Clinical Trials in MS, an international group of MS experts jointly sponsored by the National MS Society and the European Committee for Treatment and Research in MS (ECTRIMS).* A summary of this meeting has now been published in Lancet Neurology (2012 May;11(5):467-476). The Society is responding to the group’s recommendations, and sponsoring a collaborative effort to revise one clinical measure for primary use as a means of measuring disability in MS studies.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... w/pageid/7
